Table 2.

Efficacy data in 42 patients

Type of responseNumber of patients (%)
CA125
    Response7 (17)
    Less than twice baseline at 6 mo11 (26)
RECIST
    Partial response3 (9)
    Stable disease at 12 wks14 (42)
Overall best response8 (19)
Progression-free survival
    >6 mo11 (26)
    ≥2 y2 (5)